

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	December 8, 2021  May 6, 2022

## TRUDHESA™ (dihydroergotamine mesylate)

**LENGTH OF AUTHORIZATION:** Up to 6 months

**INITIAL REVIEW CRITERIA:**

- Patient must be  $\geq$  18 years of age.
- Patient must have a diagnosis of migraines.
- The drug must be prescribed for the acute treatment of migraine headaches.
- Patient must have a history of trial and failure within the last 6 months of the following:
  - One preferred triptan; **AND**
  - Concurrent use of **ONE** of the following prophylaxis products:
    - Amitriptyline
    - Beta Blocker
    - Topiramate
    - Divalproex Sodium
    - Valproic Acid

**DOSING AND ADMINISTRATION:**

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as 0.725 mg nasal spray.